Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization

References

• ALBERTS, A. W., 1990, Lovastatin and simvastatin inhibitor of HMG-CoA reductase and cholesterol biosynthesis. Cardiology, 77, 14–21.
   PubMed Web of Science ®Google Scholar
• AOKI, T., NISHIMURA, H., NAKAGAWA, S., KOHMA, J., SUZUKI, H., TAMAKI, T., WADA, Y., YOK00, N., SATO, F., KIMATA, H., KITAHARA, M., TOYODA, K., SAKASHITA, M. and SAITO, Y., 1997, Pharmacological profile of novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzme A reductase. Arzneim ForschlDrug Research, 47, 904–909.
   Google Scholar
• BABA, S., TERASAWA, Y., KIMATA, H., SHINOHARA, Y., AKIRA, K. and HASEGAWA, H., 1994, Application of radioluminography to off-line counting of radioactivity in high-performance liquid chromatographic elutes. Journal of Chromatography (A), 663, 35–41.
   Web of Science ®Google Scholar
• BOBERG, M., ANGERBAUER, R., KANHAI, W. K., KARL, W., KERN, A., RADTKE, M. and STEINKE, W., 1998, Biotransformation of cerivastatin in mice, rats, and dogs in vivo. Drug Metabolism and Disposition, 26, 640–652.
   PubMed Web of Science ®Google Scholar
• BROWN, B. G., ZHAO, X. Q., SACCO, D. E. and ALBERS, J. J., 1993, Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation, 87, 1781–1791.
   PubMed Web of Science ®Google Scholar
• BURCHELL, B., BRIERLEY, C. H. and RANCE, D., 1995, Specificity of human UDP-glucuronosyl-transferases and xenobiotic glucuronidation. Life Sciences, 57, 1819–1831.
   PubMed Web of Science ®Google Scholar
• CHRISTIANS, U., JACOBSEN, W. and FLOREN, L., 1998, Metabolism and drug interactions 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor in transplant patients: are the statins mechanistically similar? Pharmacology and Therapy, 80, 1–34.
   PubMed Web of Science ®Google Scholar
• DAIN, J. G., Fu, E., GORSKI, J., NICOLETTI, J. and SCALLEN, T. J., 1993, Biotransformation of fluvastatin sodium in humans. Drug Metabolism and Disposition, 21, 567–572.
   PubMed Web of Science ®Google Scholar
• DING, A., ZIA-AMIRHOSSEINI, P., MCDONAGH, A. F., BURLINGAME, A. L. and BENET, L. Z., 1995, Reactivity of tolmetin glucuronide with human serum albumin: identification of binding sites and mechanism of reaction by tandem mass spectrometry. Drug Metabolism and Disposition, 23, 369–376.
   Google Scholar
• FAED, E. M., 1984, Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metabolism Reviews, 15, 1213–1249.
   PubMed Web of Science ®Google Scholar
• FISCHER, V., JOHANSON, L., HEITZ, F., TULLMAN, R., GRAHAM, E., BALDECK, J. P. and ROBINSON, W. T., 1999, The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fiuvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metabolism and Disposition, 27, 410–416.
   PubMed Web of Science ®Google Scholar
• FUJINO, H., KOJIMA, J., YAMADA, Y., KANDA, H. and KIMATA, H., 1999a, Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4):Interspecies variation in laboratory animals and humans. Xenobiotics and Metabolic Disposition, 14, 79–91.
   Google Scholar
• FUJINO, H., YAMADA, I., KOJIMA, J., HIRANO, M., MATSUMOTO, H. and YONEDA, M., 1999b, Studies on the metabolic fate of NK-104, a new inhibitor HMG-CoA reductase (5): in vitro metabolism and plasma protein binding in animals and human. Xenobiotics and Metabolic Disposition, 14, 415–424.
   Google Scholar
• FUJINO, H., YAMADA, I., SHIMADA, S. and YONEDA, M., 2001, Simultaneous determination of taxol and its metabolites in microsomal samples by a simple thin layer chromatography assay-inhibitory effect of NK-104, a new inhibitor of HMG-CoA reductase. Journal of Chromatography ( B), 757, 143–150.
   PubMed Web of Science ®Google Scholar
• FUJINO, H., YAMADA, I., SHIMADA, S. and YONEDA, M., 2002, The metabolic fate of pitavastatin (NK-104), a new inhibitor of HMG-CoA reductase: Effects on drug-metabolizing systems in rats and humans. Arzneim ForschlDrug Research (in press).
   Google Scholar
• HAVEL, R. J. and RAPAPORT, E., 1995, Management of primary hyperlipidemia. New England Journal of Medicine, 332, 1301–1307.
   Web of Science ®Google Scholar
• ISHIGAMI, M., HONDA, T., TAKASAKI, W., IKEDA, T., KOMAI, T., ITo, K. and SUGIYAMA, Y., 2001, A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metabolism and Disposition, 29, 282–288.
   PubMed Web of Science ®Google Scholar
• JACOBSEN, W., KUHN, B., SOLDNER, A., KIRCHNER, G., SEWING, K. F., KOLLMAN, P. A., BENET, L. Z. and CHRISTIANS, U., 2000, Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metabolism and Disposition, 28, 1369–1378.
   PubMed Web of Science ®Google Scholar
• KAJINAMI, K., Koizumi, J., UEDA, K., MIYAMOTO, S., TAKEGOSHI, T. and MABUCHI, H., 2000b, Effect of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 study group. American Journal of Cardiology, 15, 178–183.
   Web of Science ®Google Scholar
• KAJINAMI, K., MABUCHI, H. and SAITO, Y., 2000a, NK-104, a novel synthetic HMG-CoA reductase inhibitor. Expert Opinions and Investigations in Drugs, 9, 2653–2661.
   PubMed Web of Science ®Google Scholar
• KEARNEY, A. S., CRAWFORD, L. F., MEHTA, S. C. and RADEBAUGH, G. W., 1993, The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharmaceutical Research, 10, 1461–1465.
   PubMed Web of Science ®Google Scholar
• KIMATA, H., FUJINO, H., KOIDE, T., YAMADA, Y., TSUNENARI, Y., YONEMITSU, M. and YANAGAWA, Y., 1998, Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): absorption, distribution, metabolism and excretion in rats. Xenobiotics and Metabolic Disposition, 13, 484–498.
   Google Scholar
• KOJIMA, J., FUJINO, H., ABE, H., YOSHIMURA, M., KANDA, H. and KIMATA, H., 1999a, Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile. Biological and Pharmacological Bulletin, 22, 142–150.
   PubMed Web of Science ®Google Scholar
• KOJIMA, J., FUJINO, H., YOSHIMURA, M., MORIKAWA, H. and KIMATA, H., 1999b, Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography (B), 724, 173–180.
   Web of Science ®Google Scholar
• KOMAI, T., KAWAI, K., TOKUI, T., TOKUI, Y., KUROIWA, C., SHIGEHARA, E. and TANAKA, M., 1992, Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys. European Journal of Drug Metabolism Pharmacokinetics, 17, 103–111.
   PubMed Web of Science ®Google Scholar
• LENNERNAS, H. and EAGER, G., 1997, Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Clinical Pharmacokinetics, 32, 403–425.
   PubMed Web of Science ®Google Scholar
• LUDWIG, E., WOLFINGER, H. and EBNER, T., 1998, Assessment of microsomal tolbutamide hydroxylation by a simple thin-layer chromatography radioactivity assay. Journal of Chromatography ( B), 707, 347–350.
   PubMed Web of Science ®Google Scholar
• MACKENZIE, P. I., OWENS, I. S., BURCHELL, B., BOCK, K. W., BAIROCH, A., BELANER, A., FOURNEL-GIGLEUX, S., GREEN, M., Hum, D. W., IYANAGI, T., LANCET, D., LOUISOT, P., MAGDALOU, J., CHOWDHURY, J. R., RITTER, J. K., SCHACHTER, H., TEPHLY, T. R., TIPTON, K. F. and NEBERT, D. W., 1997, The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics, 7, 255–269.
   Google Scholar
• SUZUKI, H., AoKi, T. and TAMAKI, T., 1999, Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. Atherosclerosis, 146, 259–270.
   PubMed Web of Science ®Google Scholar
• SUZUKI, H., YAMAZAKI, H., Aoxi, T. and TAMAKI, T., 2001, Hypolipidemic effect of NK-104 and other 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in guinea pigs. Arzneim Forschl Drug Research, 51, 38–45.
   PubMed Web of Science ®Google Scholar
• TUKEY, R. H. and STRASSBURG, C. P., 2000, Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annual Reviews in Pharmacology and Toxicology, 40, 581–616.
   PubMed Web of Science ®Google Scholar
• YAMADA, I., FUJINO H., SHIMADA, S. and YONEDA, M., 2001, Studies on the metabolic fate of pitavastatin (NK-104), a new inhibitor of HMG-CoA reductase — Is the metabolism of pitavastatin in monkey similar to that in human? Xenobiotic Metabolism and Disposition, 16 (suppl.), 291.
   Google Scholar
• YAMADA, N., SAITO, Y. and AKANUMA, Y., 2000, Effect of itavastatin on lipid metabolism in NIDDM patients with hyperlipidemia. Atherosclerosis, 151, 48.
   Google Scholar